OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement

Reuters

2025/05/08

OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement

OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2533966283"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533966283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533966283?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533966283","market":"us","top_or_hot":-1,"title":"OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-08 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KIDS","symbol_name":"Orthopediatrics Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nNDL8mYnh9:1","article_id":"2533966283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533966283","pubTimestamp":1746648385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of  million, improving from  million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidanc","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KIDS":"Orthopediatrics Corp","NDAQ":"纳斯达克OMX交易所"},"translate_title":"矫形儿科公司。报告2025年第一季度收入增长17%，实现调整后EBITDA改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KIDS":0.9,"NDAQ":0.9},"content_text":"OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n    \n\n        OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}